FLT3 and leukemia: Furthermore, leukemia cells progress toward matured states in patients treated with molecular targeted therapies against several driver mutations including mutant isocitrate dehydrogenase (IDH)1, IDH2, and FLT3, assuming that the concept of differentiation therapy is also applicable to non-APL (1).